Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 5
1949 1
1950 7
1951 10
1952 19
1953 17
1954 23
1955 18
1956 17
1957 15
1958 17
1959 23
1960 13
1961 19
1962 16
1963 14
1964 17
1965 6
1976 1
1979 3
1988 4
1989 12
1990 29
1991 30
1992 21
1993 22
1994 70
1995 209
1996 308
1997 356
1998 328
1999 407
2000 369
2001 437
2002 612
2003 678
2004 781
2005 1029
2006 1041
2007 1147
2008 1196
2009 1354
2010 1481
2011 1655
2012 1716
2013 1689
2014 1791
2015 1696
2016 1759
2017 1774
2018 1702
2019 819
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

23,380 results
Results by year
Filters applied: . Clear all
Page 1
Rheumatoid Arthritis
Sparks JA. Ann Intern Med 2019 - Review. PMID 30596879
In recent years, early diagnosis, aggressive treatment, and expanded therapeutic options of disease-modifying antirheumatic drugs have markedly improved both the management and long-term prognosis of RA....
In recent years, early diagnosis, aggressive treatment, and expanded therapeutic options of disease-modifying antirheumatic drugs hav …
Pigmented villonodular synovitis
Fałek A, et al. Folia Med Cracov 2018. PMID 30745604 Free article.
Recent advances in the management of Takayasu arteritis
Misra DP, et al. Int J Rheum Dis 2019 - Review. PMID 30698358
Among bDMARDs, anti-tumor necrosis factor alpha agents and tocilizumab may be useful in patients refractory to cDMARDs with retardation of angiographic progression, based on evidence derived from mostly retrospective case series, whereas the role of rituximab and ustekinumab needs further elucidation. ...
Among bDMARDs, anti-tumor necrosis factor alpha agents and tocilizumab may be useful in patients refractory to cDMARDs with retardati …
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Smolen JS, et al. Lancet 2019 - Clinical Trial. PMID 31130260 Free article.
BACKGROUND: Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to DMARDs. ...
BACKGROUND: Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventiona …
Hydroxychloroquine Retinal Toxicity
Proano C and Kimball GP. N Engl J Med 2019. PMID 31018072 Free article.
Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis
Chen SJ, et al. Int J Mol Sci 2019 - Review. PMID 30884802 Free PMC article.
With the growing understanding of the immunopathogenic mechanisms, increasingly novel marked and potential biologic agents have merged for the treatment of RA in recent years. In this review, we focus on the current understanding of pathogenic mechanisms, highlight novel biologic disease-modifying antirheumatic drugs (DMRADs), targeted synthetic DMRADs, and immune-modulating agents, and identify the applicable immune-mediated therapeutic strategies of the near future. ...
With the growing understanding of the immunopathogenic mechanisms, increasingly novel marked and potential biologic agents have merge …
23,380 results
Jump to page
Feedback